Transapical Transcatheter Aortic Valve Replacement
Transcatheter aortic valve replacement has become an acceptable and increasingly common treatment for aortic stenosis. While its use was initially limited to patients deemed prohibitively high risk for surgery, indications for transcatheter therapy continue to expand. Although the transfemoral route is increasingly utilized, the transapical approach is an indispensable part of the surgeon’s armamentarium for difficult-access patients. Moreover, since future transcatheter interventions will likely utilize the transapical approach, it is incumbent on cardiac surgeons to become facile with this exposure.
KeywordsTranscatheter aortic valve replacement TAVR Transapical Aortic stenosis PARTNER trial
- 7.Nishimura RA, Otto CM, Bonow RO, et al. AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American college of cardiology/American heart association task force on practice guidelines. J Am Coll Cardiol. 2014;63(22):e57–185. doi: 10.1016/j.jacc.2014.02.536.CrossRefPubMedGoogle Scholar
- 8.Miller DC, Blackstone EH, MacK MJ, et al. Transcatheter (TAVR) versus surgical (AVR) aortic valve replacement: occurrence, hazard, risk factors, and consequences of neurologic events in the PARTNER trial. J Thorac Cardiovasc Surg. 2012;143(4):832–43. doi: 10.1016/j.jtcvs.2012.01.055.CrossRefPubMedGoogle Scholar
- 9.Blackstone EH, Suri RM, Rajeswaran J, Babaliaros V, Douglas PS, Fearon WF, Miller DC, Hahn RT, Kapadia S, Kirtane AJ, Kodali SK, Mack M, Szeto WY, Thourani VH, Tuzcu EM, Williams MR, Akin JJ, Leon MBSL. Propensity-matched comparison of clinical outcomes after transapical vs. transfemoral TAVR. Circulation. 2015;131(22):1989–2000.CrossRefPubMedGoogle Scholar